Servier is the second largest French pharmaceutical company with over 3,000 researchers focused on novel treatments for cardiovascular disease, oncology, diabetes, CNS, and Rheumatology.

This partnership is a boon for researchers on both sides of the Atlantic, bringing together Servier’s decades of expertise and QB3@953’s innovative thinking and startup community. Servier will receive a “golden ticket,” which allows Servier to award a bench to a startup company. Servier’s Golden Ticket grant will give a promising Bay Area biotech company access to QB3’s millions of dollars of state-of-the-art research equipment, as well as the opportunity to build a research relationship with an international pharma leader.